Cutaneous melanoma: Interferon alpha adjuvant therapy for patients at high risk for recurrent disease

Dermatologic Therapy

Volumn 19, Issue 1, 2006, Pages 9-18

  Lens, Marko ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; High risk melanoma; Interferon alpha; Melanoma therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA2C INTERFERON; CISPLATIN; DACARBAZINE; GANGLIOSIDE GM2; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LIVER ENZYME; PEGINTERFERON ALPHA2A; QS 21; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; VINBLASTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; FATIGUE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HEADACHE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; QUALITY OF LIFE; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; WEIGHT REDUCTION;

CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645064843     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2005.00051.x     Document Type: Review

References (42)

1. O'Day SJ Kim CJ Reintgen DS Metastatic melanoma: chemotherapy to biochemotherapy Cancer Control 2002 9 31 38
2. Sanjiv SA Kirkwood JM Update on the role of adjuvant interferon for high risk melanoma Forum 2000 10 230 239
3. Anderson CM Buzaid AC Legha SS Systemic treatments for advanced cutaneous melanoma Oncology (Huntingt) 1995 9 1149 1158
4. Newby JC Eisen T The role of chemotherapy In Newton Bishop JA Gore M eds MelanomaCritical debates
5. Whittaker S Adjuvant therapy in melanoma Clin Exp Dermatol 2000 25 497 502
6. Nathan PD Eisen TG The biological treatment of renal-cell carcinoma and melanoma Lancet Oncol 2002 3 89 96
7. Buzaid AC Legha SS Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma Semin Oncol 1994 21 23 28
8. Eggermont AM European approach to the treatment of malignant melanoma Curr Opin Oncol 2002 14 205 211
9. Isaacs A Lindenmann J Virus interference I Proc R Soc Lond 1957 147 258 267
10. Jonasch E Haluska FG Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities The Oncologist 2001 6 34 55
11. Pfeffer LM Dinarello CA Herberman RB et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons Cancer Res 1998 58 2489 2499
12. Pestka S Langer JA Zoon KC Samuel CE Interferons and their actions Ann Rev Biochem 1987 56 727 777
13. Borden EC Interferons: pleiotropic cellular modulators Clin Immunol Immunopathol 1992 62 S18 S24
14. Grander D Einhorn S Interferon and malignant disease - how does it work and why doesn't it always? Acta Oncol 1998 37 331 338
15. Newmark P Engineered E. coli produces interferon Nature 1980 283 323
16. Pestka S Cloning of the human interferons Methods Enzymol 1981 79 599 601
17. Pehamberger H Soyer HP Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma J Clin Oncol 1998 16 1425 1429
18. Grob JJ Dreno B de la Salmoniere P et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases Lancet 1998 351 1905 1910
19. Cascinelli N Belli F MacKie R Santinami M Bufalino R Morabito A Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial Lancet 2001 358 866 869
20. Kirkwood JM Ibrahim JG Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 2000 18 2444 2458
21. Cameron DA Cornbleet MC Mackie RM et al. Adjuvant interferon alpha 2b in high risk melanoma- the Scottish study Br J Cancer 2001 84 1146 1149
22. Hancock BW Wheatley K Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH study - United Kingdom coordinating committee on cancer research randomised study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma J Clin Oncol 2004 22 53 61
23. Eggermont AM Punt CJ Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival? Am J Clin Dermatol 2003 4 531 536
24. Kirkwood JM Strawderman MH Ernstoff MS Smith TJ Borden EC Blum RH Interferon alfa 2-b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 1996 14 7 17
25. Creagan ET Dalton RJ Ahmann DL et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 1995 13 2776 2783
26. Kirkwood JM Ibrahim JG Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 2001 19 2370 2380
27. Kirkwood JM Ibrahim J Lawson DH et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696 J Clin Oncol 2001 19 1430 1436
28. Cascinelli N Bufalino R Morabito A MacKie R Results of adjuvant interferon study in WHO melanoma programme Lancet 1994 345 913 914
29. Kirkwood JM Manola J Ibrahim J Sondak V Ernstoff MS Rao U A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma Clin Cancer Res 2004 10 1670 1677
30. Wheatley K Ives N Hancock B et al. Does adjuvant interferon-alfa for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials Cancer Treat Rev 2003 29 241 252
31. Moschos SJ Kirkwood JM Konstantinopoulos PA Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b J Clin Oncol 2004 22 11 14
32. Hancock B Wheatley K Ives N Gore M Adjuvant interferon therapy for melanoma J Clin Oncol 2005 23 2431
33. Schuchter LM Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol 2004 22 7 10
34. Kimayai-Asadi A Usman A The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence J Am Acad Dermatol 2000 43 708 711
35. Lafuma A Dreno B Delaunay M et al. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma Eur J Cancer 2001 37 369 375
36. Hillner BE Kirkwood JM Atkins MB Johnson ER Smith TJ Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684 J Clin Oncol 1997 15 2351 2358
37. Kirkwood JM Bender C Agarwala S et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy J Clin Oncol 2002 20 3703 3718
38. Kilbridge KL Cole BF Kirkwood JM et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data J Clin Oncol 2002 20 1311 1318
39. National Cancer Institute, U.S. National Institutes of Health at. Accessed April 1, 2005
40. Gogas H Bafaloukos D Ioannovich J et al. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year - a Hellenic Cooperative Oncology Group study Anticancer Res 2004 24 1947 1952
41. Eggermont AM Keilholz U Testori A Cook M Lienard D Ruiter DJ The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer Ann Surg Oncol 2001 8 9 Suppl. 38S 40S
42. McMasters KM Noyes RD Reintgen DS et al. Lessons learned from the Sunbelt Melanoma Trial J Surg Oncol 2004 86 212 223